Literature DB >> 29344344

Acetylcholinesterase inhibitors in treatment-resistant psychotic depression.

Chris Smart1, Hamish McAllister-Williams2, David Andrew Cousins2.   

Abstract

Dopamine receptor antagonists can be effective in psychotic depression but response is not assured. Visual hallucinations may arise from a dysregulation of brain cholinergic systems and acetylcholinesterase inhibitors (AChEIs) can treat such hallucinations in dementia with Lewy bodies (DLB). AChEIs have been used in schizophrenia with some success but their efficacy and tolerability in psychotic depression is unclear. This striking case illustrates AChEIs specifically targeting multimodal hallucinations in treatment-resistant depression. To our knowledge it is the first case report to do so. It highlights the value of delineating psychopathology when considering novel interventions. This case also shows the idiosyncratic nature of side effects and the importance of pursuing different drugs within class.

Entities:  

Keywords:  acetylcholinesterase inhibitors; multimodal hallucinations; psychotic depression; treatment resistance

Year:  2017        PMID: 29344344      PMCID: PMC5761905          DOI: 10.1177/2045125317718810

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN: 2045-1253


  9 in total

Review 1.  Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a review of the literature.

Authors:  Sachin S Patel; Azizah Attard; Pamela Jacobsen; Sukhi Shergill
Journal:  BMC Psychiatry       Date:  2010-09-07       Impact factor: 3.630

Review 2.  Acetylcholinesterase inhibitors for schizophrenia.

Authors:  Jasvinder Singh; Kamalpreet Kour; Mahesh B Jayaram
Journal:  Cochrane Database Syst Rev       Date:  2012-01-18

3.  Long-term efficacy of donepezil for relapse of visual hallucinations in patients with dementia with Lewy bodies.

Authors:  Katsuyuki Ukai; Hiroshige Fujishiro; Shuji Iritani; Norio Ozaki
Journal:  Psychogeriatrics       Date:  2014-12-16       Impact factor: 2.440

4.  Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.

Authors:  Anantha Shekhar; William Z Potter; Jeffrey Lightfoot; John Lienemann; Sanjay Dubé; Craig Mallinckrodt; Frank P Bymaster; David L McKinzie; Christian C Felder
Journal:  Am J Psychiatry       Date:  2008-07-01       Impact factor: 18.112

Review 5.  Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data.

Authors:  Connie Sanchez; Karen E Asin; Francesc Artigas
Journal:  Pharmacol Ther       Date:  2014-07-09       Impact factor: 12.310

6.  Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's disease.

Authors:  Fiore Manganelli; Carmine Vitale; Gabriella Santangelo; Chiara Pisciotta; Rosa Iodice; Autilia Cozzolino; Raffaele Dubbioso; Marina Picillo; Paolo Barone; Lucio Santoro
Journal:  Brain       Date:  2009-07-07       Impact factor: 13.501

7.  Donepezil delays progression to AD in MCI subjects with depressive symptoms.

Authors:  P H Lu; S D Edland; E Teng; K Tingus; R C Petersen; J L Cummings
Journal:  Neurology       Date:  2009-06-16       Impact factor: 9.910

8.  Musical hallucinations treated with acetylcholinesterase inhibitors.

Authors:  Jan Dirk Blom; Jan Adriaan F Coebergh; René Lauw; Iris E C Sommer
Journal:  Front Psychiatry       Date:  2015-04-07       Impact factor: 4.157

Review 9.  Pharmacological treatment for psychotic depression.

Authors:  Jaap Wijkstra; Jeroen Lijmer; Huibert Burger; Andrea Cipriani; John Geddes; Willem A Nolen
Journal:  Cochrane Database Syst Rev       Date:  2015-07-30
  9 in total
  2 in total

Review 1.  The Pharmacology of Visual Hallucinations in Synucleinopathies.

Authors:  Mirella Russo; Claudia Carrarini; Fedele Dono; Marianna Gabriella Rispoli; Martina Di Pietro; Vincenzo Di Stefano; Laura Ferri; Laura Bonanni; Stefano Luca Sensi; Marco Onofrj
Journal:  Front Pharmacol       Date:  2019-12-09       Impact factor: 5.810

Review 2.  Repurposing Cholinesterase Inhibitors as Antidepressants? Dose and Stress-Sensitivity May Be Critical to Opening Possibilities.

Authors:  Paul J Fitzgerald; Pho J Hale; Anjesh Ghimire; Brendon O Watson
Journal:  Front Behav Neurosci       Date:  2021-01-14       Impact factor: 3.558

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.